Amkay Pharmaceutical (603087.SH): GZR102 injection Phase I clinical trial completed the first dose of medication given to the subject.

According to the Wise Financial News APP, Ganli Pharmaceutical (603087.SH) announced that the company's independently developed GZR102 injection is currently undergoing Phase I clinical trials in China, and the first subject has successfully received the drug recently.